Xtent looks to raise $75m at IPO (initial public offering)
This article was originally published in Clinica
Executive Summary
Menlo Park, California-based drug-eluting stent developer Xtent last week priced its initial public offering of 4.7 million shares at $16 per share.The stock will be listed on the Nasdaq under the symbol "XTNT". A further 705,000 shares have been optioned to the underwriters to cover over-allotments, if any.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.